HUE033388T2 - Kompozíciók dopa dekarboxiláz inhibitorok folyamatos bevezetésére - Google Patents
Kompozíciók dopa dekarboxiláz inhibitorok folyamatos bevezetésére Download PDFInfo
- Publication number
- HUE033388T2 HUE033388T2 HUE10725880A HUE10725880A HUE033388T2 HU E033388 T2 HUE033388 T2 HU E033388T2 HU E10725880 A HUE10725880 A HU E10725880A HU E10725880 A HUE10725880 A HU E10725880A HU E033388 T2 HUE033388 T2 HU E033388T2
- Authority
- HU
- Hungary
- Prior art keywords
- carbidopa
- levodopa
- composition
- administration
- arginine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/10—Hydrazines
- C07C243/12—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms
- C07C243/16—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C243/18—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (3)
- Ko^po^idô, amely: larislffîa^ grginiïî^ levodopát tos Rarbidopàt (őarbiöpa), ahoi az említett kompozíció tartalma? legalább 4 tömeg % levodopát, olyan tevcdopa-arglnin móisránnyal (molar ratio} rendelkezik, amely az 1:1,5· és 1:2,5 közötti tartományban van, pH-ja a 8,5 és 10 közötti tartományban van, és stabil 25*0 hőmérsékleten 48 érán át vagy tovább,
- 2, Az 1. igénypont szerinti gyógyászatiig elfogadható folyékony kompozíció, amely tartalmaz továbbá egy gyógyászatiig elfogadható kötőanyagot (excipient), amely előnyösen a következők közűi választható ki; N-metihpirroildon, poiívteilpirrolidcn, propiiéngükol, ariíioxldánsok, és mindezek kombinációi. k Az 1. vagy 2. igénypont szerinti gyógyászatiéig elfogadható folyékony kompozíció, amely tartalmaz továbbá vizet, 4. M 14. igénypontok bármelyike szerinti gyógyászatslag elfogadható folyékony kompozíció, amely tartalmaz továbbá entákápom (entacapcne) vagy toikapontioi^pone).
- 5. Az 1-4, igénypontok bármelyike szerinti gyógyászatliag elfogadható folyékony kompozíció, kbmpæicüôölyaíj; pH-val bír, amely a mintegy 8,5 és niintegy 9,5 közötti tartosnányban vac 25C hőmérsékleten, 6 Késztet (kit), amely tartalmaz a) egy első kompozíciót, amely alkalmas folyamatos bevezetéshez, és tartaímazzá az 14, igénypontok bármelyike szerinti folyékony kompozíciót; és b) egy második kompozíciót, amely-alkalmas orális bevezetésre, és tartalmaz levodopát vagy ennek gyógyászaíiíag elfogadható sóját vagy észterét. 7 A 6. igénypont szerint! készlet, ahol az első kompozíció a folyamatos bevezetéshez bőrön keresztüli (transdermsí}; intradermális, bor á!alti (subcutaneous), intravénás. Vagy nyowbéien belük (intraduodenaí) bevezetéshez való. 8: A ?. igénypont szerinti készlet, ahol az említett folyamatos ;bevezetés tartalmazza infúztos szivattyú (pump) alkalmazását, 9. A 6-8. ôibâhiïÎiëiiÿikë: iëâéflpitf ikészíet, ahol a másodok kompozíció tartalmaz továbbá ksr^Ösigíilitij ·:;^ίίι^ίίίί^(0<3ί··: SPenserazide), entakapont, íolkapont, vagy ezek kombinációiét. 10. A 6-9. Igénypontok bármelyike szerinti késztet, ahefea második köíhpóztoió tartalmazza íevodöpá gyógyászafiteg elfogadható sóját, előnyösen levotíops arginin sóját. 11. A 8-10. igénypontok bármelyike szerinti készlet alkalmazáshoz neurológiai rendellenességek kezelésében, amelyek a következők közül választhatók ki: nyugtalan láb (restless leg) szindróma. Parkinson kór, másodlagos parklnzonizmus. ttetington kór, vágy Parttosomszérő szjhórótnl, áttol s kezeléS^ àZ éiso kompzíSé folyamatos bevezetése a másödil kompozícióval együtt 12: A11. igénypont szerinti készlet alkalmazáshoz Parkinson kor kezeléséhez vsgy enyhítéséhez.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17951109P | 2009-05-19 | 2009-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE033388T2 true HUE033388T2 (hu) | 2017-12-28 |
Family
ID=42320738
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17158360A HUE052685T2 (hu) | 2009-05-19 | 2010-05-17 | Dopa-dekarboxiláz inhibitorok folyamatos adagolására szolgáló készítmények |
| HUE10725880A HUE033388T2 (hu) | 2009-05-19 | 2010-05-17 | Kompozíciók dopa dekarboxiláz inhibitorok folyamatos bevezetésére |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17158360A HUE052685T2 (hu) | 2009-05-19 | 2010-05-17 | Dopa-dekarboxiláz inhibitorok folyamatos adagolására szolgáló készítmények |
Country Status (26)
| Country | Link |
|---|---|
| US (9) | US8193243B2 (hu) |
| EP (3) | EP3192500B1 (hu) |
| JP (3) | JP5643297B2 (hu) |
| KR (2) | KR101641401B1 (hu) |
| CN (2) | CN104546700B (hu) |
| AR (3) | AR078413A1 (hu) |
| AU (1) | AU2010250766B2 (hu) |
| BR (1) | BRPI1011031B8 (hu) |
| CA (1) | CA2761624C (hu) |
| CL (1) | CL2011002895A1 (hu) |
| CY (1) | CY1119495T1 (hu) |
| DK (2) | DK2432454T3 (hu) |
| ES (2) | ES2840748T3 (hu) |
| HR (2) | HRP20170805T1 (hu) |
| HU (2) | HUE052685T2 (hu) |
| IL (1) | IL216383A (hu) |
| LT (1) | LT2432454T (hu) |
| MX (2) | MX2011012315A (hu) |
| NZ (1) | NZ596963A (hu) |
| PL (2) | PL3192500T3 (hu) |
| PT (2) | PT3192500T (hu) |
| RU (3) | RU2678839C2 (hu) |
| SG (3) | SG10201505101VA (hu) |
| SI (1) | SI2432454T1 (hu) |
| WO (1) | WO2010134074A1 (hu) |
| ZA (1) | ZA201109037B (hu) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN192600B (hu) * | 1996-10-18 | 2004-05-08 | Hoechst Celanese Corp | |
| PT3192500T (pt) | 2009-05-19 | 2021-01-05 | Neuroderm Ltd | Composições para a administração contínua de inibidores da dopa decarboxilase |
| SG10201509316SA (en) * | 2010-11-15 | 2015-12-30 | Neuroderm Ltd | Continuous Administration Of L-Dopa, Dopa Decarboxylase Inhibitors, Catechol-O-Methyl Transferase Inhibitors And Compositions For Same |
| DK2854764T3 (en) | 2012-06-05 | 2019-04-08 | Neuroderm Ltd | COMPOSITIONS CONTAINING APOMORPHINE AND ORGANIC ACIDS, AND APPLICATIONS THEREOF |
| ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
| CN103845318A (zh) * | 2012-12-07 | 2014-06-11 | 天津市汉康医药生物技术有限公司 | 恩他卡朋分散片 |
| BR112015022390A8 (pt) * | 2013-03-13 | 2019-11-26 | Neuroderm Ltd | uso de carbidopa, levodopa e um inibidor de comt para a preparação de uma composição para tratamento de doença de parkinson |
| JP6538063B2 (ja) * | 2013-11-05 | 2019-07-03 | シンアジャル コーポレイション | 口を介する連続的薬物送達のためのデバイスおよび方法 |
| ES2967693T3 (es) * | 2014-03-13 | 2024-05-03 | Neuroderm Ltd | Composiciones del inhibidor de la dopa descarboxilasa |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| EP4356907A1 (en) * | 2014-09-04 | 2024-04-24 | LobSor Pharmaceuticals Aktiebolag | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comtinhibitor and method of administration thereof |
| PT3209302T (pt) | 2014-10-21 | 2019-07-19 | Abbvie Inc | Profármacos de carbidopa e l-dopa e a sua utilização para tratar doença de parkinson |
| MA41377A (fr) | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
| AU2016258179B2 (en) | 2015-05-06 | 2021-07-01 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
| US10555922B2 (en) | 2015-09-04 | 2020-02-11 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| CN108495617A (zh) | 2015-11-24 | 2018-09-04 | 纽罗德姆有限公司 | 包含左旋多巴酰胺的药物组合物和其用途 |
| JP7095873B2 (ja) | 2016-04-11 | 2022-07-05 | ユニバーシティ・オブ・キャンベラ | レボドパ、抗酸化剤及び水性担体を含む眼科用組成物 |
| US10064834B2 (en) | 2016-05-09 | 2018-09-04 | Texas Tech University System | Carbidopa for the treatment of cancer |
| LT3634384T (lt) * | 2017-06-05 | 2021-07-12 | Dizlin Pharmaceuticals Ab | Levadopos infuzijos tirpalas |
| US20230123806A1 (en) * | 2017-07-07 | 2023-04-20 | Neuroderm, Ltd. | Device for subcutaneous delivery of fluid medicament |
| EP3773532A4 (en) * | 2018-03-29 | 2022-11-02 | Avion Pharmaceuticals, LLC | FRACTIONAL LEVODOPA DOSAGE AND USE |
| US20220226269A1 (en) * | 2019-06-12 | 2022-07-21 | President And Fellows Of Harvard College | Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| WO2023126945A1 (en) * | 2022-01-03 | 2023-07-06 | Neuroderm, Ltd. | Methods and compositions for treating parkinson's disease |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3769424A (en) * | 1970-10-01 | 1973-10-30 | Merck & Co Inc | Composition and method of treating dopamine deficiency in brain tissue |
| AU6889274A (en) * | 1973-05-17 | 1975-11-20 | Astra Laekemedel Ab | Treatment of neurological disorders |
| US3936495A (en) | 1973-11-27 | 1976-02-03 | Merck & Co., Inc. | Purification process |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4241082A (en) | 1977-09-02 | 1980-12-23 | Sankyo Company Limited | Agents for promoting reproductive ability of domestic animals |
| JPS5450700A (en) | 1977-09-28 | 1979-04-20 | Sankyo Co | Glazing agent of animal leather |
| JPS6021570B2 (ja) * | 1978-07-04 | 1985-05-28 | 三共株式会社 | ド−パ類の高濃度製剤の製法 |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4642316A (en) | 1985-05-20 | 1987-02-10 | Warner-Lambert Company | Parenteral phenytoin preparations |
| ATE76747T1 (de) | 1986-06-10 | 1992-06-15 | Chiesi Farma Spa | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. |
| US4684666A (en) | 1986-08-19 | 1987-08-04 | Haas Pharmaceuticals, Inc. | Stabilized liquid analgesic compositions |
| US4963568A (en) | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| CA2058975C (en) | 1990-10-30 | 2000-06-06 | Shuichi Kasai | Antiinflammatory gel preparation |
| US5877176A (en) | 1991-12-26 | 1999-03-02 | Cornell Research Foundation, Inc. | Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis |
| CA2143070C (en) * | 1994-02-22 | 2001-12-18 | Pankaj Modi | Oral controlled release liquid suspension pharmaceutical formulation |
| GB9523833D0 (en) | 1995-11-22 | 1996-01-24 | Boots Co Plc | Medical treatment |
| US5861423A (en) | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| WO1999048876A1 (en) | 1998-03-20 | 1999-09-30 | Warner-Lambert Company | Crystalline sodium phenytoin monohydrate |
| US7201923B1 (en) | 1998-03-23 | 2007-04-10 | General Mills, Inc. | Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
| PL204921B1 (pl) | 1998-05-15 | 2010-02-26 | Warner Lambert Co | Stabilizowana kompozycja farmaceutyczna zawierająca 4-amino-3-podstawioną pochodną kwasu butanowego i α-aminokwas oraz sposób jej wytwarzania |
| US6274168B1 (en) | 1999-02-23 | 2001-08-14 | Mylan Pharmaceuticals Inc. | Phenytoin sodium pharmaceutical compositions |
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| AU3490300A (en) | 1999-03-12 | 2000-10-04 | Nitromed, Inc. | Dopamine agonists in combination with nitric oxide donors, compositions and methods of use |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US7479498B2 (en) | 1999-08-23 | 2009-01-20 | Phoenix Biosciences, Inc. | Treatments for viral infections |
| US6348965B1 (en) | 1999-09-24 | 2002-02-19 | Henry Palladino | Solid state fluorescence and absorption spectroscopy |
| SE0001151D0 (sv) | 2000-03-31 | 2000-03-31 | Amarin Dev Ab | Method for producing a controlled-release composition |
| US20020028799A1 (en) | 2000-07-06 | 2002-03-07 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
| GB0017387D0 (en) | 2000-07-14 | 2000-08-30 | Pfizer Ltd | Novel enzyme |
| US20020099013A1 (en) | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
| US20030119714A1 (en) | 2000-12-15 | 2003-06-26 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
| WO2003050261A2 (en) | 2001-12-10 | 2003-06-19 | Bristol-Myers Squibb Company | (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase |
| BR0309113A (pt) | 2002-04-11 | 2005-02-01 | Ranbaxy Lab Ltd | Composições farmacêuticas de liberação controlada de carbidopa e levodopa e processo para a preparação das mesmas |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| CA2500320A1 (en) | 2002-10-10 | 2004-04-29 | Morphochem Aktiengesellschaft Fuer Kombinatorische Chemie | Novel compounds with antibacterial activity |
| EP1646445A4 (en) | 2003-07-18 | 2007-09-19 | Baxter Int | METHOD OF MANUFACTURING, USING AND COMPOSING SMALL BALLULAR PARTICLES PRODUCED BY CONTROLLED PHASE SEPARATION |
| US8173840B2 (en) | 2003-07-29 | 2012-05-08 | Signature R&D Holdings, Llc | Compounds with high therapeutic index |
| US7589233B2 (en) | 2003-07-29 | 2009-09-15 | Signature R&D Holdings, Llc | L-Threonine derivatives of high therapeutic index |
| GB0319935D0 (en) | 2003-08-26 | 2003-09-24 | Cipla Ltd | Polymorphs |
| US20050070608A1 (en) * | 2003-08-29 | 2005-03-31 | Julius Remenar | Pharmaceutical compositions and method of using levodopa and carbidopa |
| US20050053669A1 (en) | 2003-09-05 | 2005-03-10 | Boehringer Ingelheim International Gmbh | Administration form for the oral application of poorly soluble acidic and amphorteric drugs |
| CN1901879A (zh) * | 2003-10-31 | 2007-01-24 | 阿尔扎公司 | 左旋多巴和卡比多巴的给药 |
| AU2004285533A1 (en) | 2003-10-31 | 2005-05-12 | Alza Corporation | Compositions and dosage forms for enhanced absorption |
| WO2005099678A1 (en) | 2004-04-06 | 2005-10-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| SE0401842D0 (sv) * | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| WO2006029411A2 (en) | 2004-09-09 | 2006-03-16 | Yeda Research And Development Co. Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
| WO2006037061A2 (en) * | 2004-09-28 | 2006-04-06 | Farouk Karoum | Compositions and methods of using d-dopa to treat parkinson's disease |
| WO2006043532A1 (ja) * | 2004-10-19 | 2006-04-27 | Ono Pharmaceutical Co., Ltd. | パーキンソン病治療剤 |
| DE102006021872B4 (de) | 2006-05-11 | 2008-04-17 | Sanofi-Aventis | 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| UA95954C2 (ru) | 2006-05-31 | 2011-09-26 | Солвей Фармасьютикалс Гмбх | Продолжительное 24-часовое введение в кишечник леводопа/карбидопа |
| CA2606658A1 (en) | 2006-10-13 | 2008-04-13 | Mike Tyers | Compositions and methods for treating neurological disorders or damage |
| CA2682888A1 (en) * | 2007-04-06 | 2008-10-16 | Transform Pharmaceuticals, Inc. | Systems and methods for delivering a fluid drug |
| CN101669925B (zh) | 2008-09-10 | 2011-08-10 | 天津药物研究院 | 干粉吸入剂、其制备方法和用途 |
| US20130253056A1 (en) | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
| PT3192500T (pt) | 2009-05-19 | 2021-01-05 | Neuroderm Ltd | Composições para a administração contínua de inibidores da dopa decarboxilase |
| CN101987081B (zh) | 2010-07-16 | 2012-08-08 | 钟术光 | 一种控释制剂 |
| KR101187064B1 (ko) | 2010-07-18 | 2012-09-28 | 주식회사 바이오폴리메드 | 양이온성 지질, 이의 제조 방법 및 이를 포함하는 세포내 이행성을 갖는 전달체 |
| US10150792B2 (en) | 2010-11-08 | 2018-12-11 | Synthonics, Inc. | Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients |
| SG10201509316SA (en) | 2010-11-15 | 2015-12-30 | Neuroderm Ltd | Continuous Administration Of L-Dopa, Dopa Decarboxylase Inhibitors, Catechol-O-Methyl Transferase Inhibitors And Compositions For Same |
| TR201808178T4 (tr) | 2010-11-15 | 2018-07-23 | Neuroderm Ltd | Aktif ajanların transdermal dağıtımı için bileşimler. |
| WO2012079072A2 (en) | 2010-12-10 | 2012-06-14 | Synagile Corporation | Subcutaneously infusible levodopa prodrug compositions and methods of infusion |
| WO2013061161A2 (en) | 2011-10-28 | 2013-05-02 | Green Bcn Consulting Services Sl | New combination therapies for treating neurological disorders |
| BR112015022390A8 (pt) | 2013-03-13 | 2019-11-26 | Neuroderm Ltd | uso de carbidopa, levodopa e um inibidor de comt para a preparação de uma composição para tratamento de doença de parkinson |
| ES2967693T3 (es) | 2014-03-13 | 2024-05-03 | Neuroderm Ltd | Composiciones del inhibidor de la dopa descarboxilasa |
-
2010
- 2010-05-17 PT PT171583602T patent/PT3192500T/pt unknown
- 2010-05-17 PL PL17158360T patent/PL3192500T3/pl unknown
- 2010-05-17 SG SG10201505101VA patent/SG10201505101VA/en unknown
- 2010-05-17 SG SG10201709016RA patent/SG10201709016RA/en unknown
- 2010-05-17 RU RU2015115064A patent/RU2678839C2/ru active
- 2010-05-17 CN CN201410800432.0A patent/CN104546700B/zh active Active
- 2010-05-17 AU AU2010250766A patent/AU2010250766B2/en active Active
- 2010-05-17 ES ES17158360T patent/ES2840748T3/es active Active
- 2010-05-17 DK DK10725880.8T patent/DK2432454T3/en active
- 2010-05-17 WO PCT/IL2010/000400 patent/WO2010134074A1/en active Application Filing
- 2010-05-17 SI SI201031466T patent/SI2432454T1/sl unknown
- 2010-05-17 PT PT107258808T patent/PT2432454T/pt unknown
- 2010-05-17 US US12/781,357 patent/US8193243B2/en active Active
- 2010-05-17 EP EP17158360.2A patent/EP3192500B1/en active Active
- 2010-05-17 KR KR1020117030315A patent/KR101641401B1/ko active IP Right Grant
- 2010-05-17 HU HUE17158360A patent/HUE052685T2/hu unknown
- 2010-05-17 MX MX2011012315A patent/MX2011012315A/es active IP Right Grant
- 2010-05-17 LT LTEP10725880.8T patent/LT2432454T/lt unknown
- 2010-05-17 EP EP10725880.8A patent/EP2432454B1/en active Active
- 2010-05-17 MX MX2015001674A patent/MX364974B/es unknown
- 2010-05-17 RU RU2011149976/15A patent/RU2559083C9/ru active
- 2010-05-17 KR KR1020167019114A patent/KR101709904B1/ko active IP Right Grant
- 2010-05-17 HU HUE10725880A patent/HUE033388T2/hu unknown
- 2010-05-17 JP JP2012511409A patent/JP5643297B2/ja active Active
- 2010-05-17 NZ NZ596963A patent/NZ596963A/en not_active IP Right Cessation
- 2010-05-17 CA CA2761624A patent/CA2761624C/en active Active
- 2010-05-17 DK DK17158360.2T patent/DK3192500T3/da active
- 2010-05-17 ES ES10725880.8T patent/ES2627655T3/es active Active
- 2010-05-17 BR BRPI1011031A patent/BRPI1011031B8/pt active IP Right Grant
- 2010-05-17 SG SG2011085297A patent/SG176159A1/en unknown
- 2010-05-17 EP EP20197759.2A patent/EP3777839A1/en active Pending
- 2010-05-17 PL PL10725880T patent/PL2432454T3/pl unknown
- 2010-05-17 CN CN201080022208.3A patent/CN102438587B/zh active Active
- 2010-05-19 AR ARP100101735A patent/AR078413A1/es not_active Application Discontinuation
- 2010-07-14 US US12/836,130 patent/US7863336B2/en active Active
- 2010-12-07 US US12/961,534 patent/US9101663B2/en active Active
-
2011
- 2011-11-15 IL IL216383A patent/IL216383A/en active IP Right Grant
- 2011-11-17 CL CL2011002895A patent/CL2011002895A1/es unknown
- 2011-12-08 ZA ZA2011/09037A patent/ZA201109037B/en unknown
-
2014
- 2014-05-13 US US14/276,235 patent/US9040590B2/en active Active
- 2014-05-13 US US14/276,211 patent/US9040589B2/en active Active
- 2014-10-30 JP JP2014221786A patent/JP5921002B2/ja active Active
-
2015
- 2015-07-01 US US14/789,214 patent/US9993451B2/en active Active
-
2016
- 2016-04-08 JP JP2016078121A patent/JP6157678B2/ja active Active
-
2017
- 2017-05-30 HR HRP20170805TT patent/HRP20170805T1/hr unknown
- 2017-05-31 CY CY20171100573T patent/CY1119495T1/el unknown
-
2018
- 2018-05-30 US US15/992,979 patent/US20190125708A1/en not_active Abandoned
-
2019
- 2019-01-16 RU RU2019101159A patent/RU2019101159A/ru unknown
- 2019-03-28 AR ARP190100805A patent/AR117412A2/es unknown
- 2019-12-23 AR ARP190103847A patent/AR117502A2/es unknown
-
2020
- 2020-04-30 US US16/863,459 patent/US20210077442A1/en not_active Abandoned
- 2020-12-21 HR HRP20202038TT patent/HRP20202038T1/hr unknown
-
2022
- 2022-11-11 US US17/985,556 patent/US20230321019A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230321019A1 (en) | Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same | |
| US20170196828A1 (en) | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same | |
| RU2684105C2 (ru) | Композиции ингибитора дофа-декарбоксилазы | |
| WO2012066538A1 (en) | Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same | |
| US10258585B2 (en) | DOPA decarboxylase inhibitor compositions |